Objective: To estimate the cost-effectiveness of using continuous positive airway pressure (CPAP) in the management of patients suffering from severe obstructive sleep apnoea/hypopnoea syndrome (OSAHS), compared to no treatment, from the perspective of the UK's National Health Service (NHS).
Methods: A Markov model was constructed to assess the cost-effectiveness of CPAP compared to no treatment. The model depicted the management of a 55 year old patient with severe OSAHS as defined by an apnoea-hypopnoea index (AHI) >30 and daytime sleepiness (Epworth scale score >12). The model spans a period of 14 years.
Results: According to the model, 57% of untreated patients are expected to be alive at the end of 14 years compared to 72% of CPAP-treated patients. Untreated patients are expected to cost the NHS £10,645 (95% CI: £7,988; £14,098) per patient over 14 years compared to £9,672 (95% CI: £8,057; £12,860) per CPAP-treated patients. Treatment with CPAP for a period of one year was found not to be a cost-effective option since the cost per QALY gained is expected to be >£20,000, but after two years of treatment the cost per QALY gained is expected to be £10,000 or less and after 13 years of treatment, CPAP becomes a dominant treatment (i.e. more effective than no treatment for less cost).
Conclusion: Within the limitations of our model, CPAP was found to be clinically more effective than no treatment and the cost-effective strategy, from the perspective of the UK's NHS, after a minimum of 2 years' treatment.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.